Skip to main content
PMC home page
Transactions of the American Ophthalmological Society logoLink to Transactions of the American Ophthalmological Society
. 2001;99:319–343.

Enhancement of scleral macromolecular permeability with prostaglandins.

R N Weinreb 1
PMCID: PMC1359020  PMID: 11797317

Abstract

PURPOSE: It is proposed that the sclera is a metabolically active and pharmacologically responsive tissue. These studies were undertaken to determine whether prostaglandin exposure can enhance scleral permeability to high-molecular-weight substances. METHODS: Topical prostaglandin F2 alpha (PGF2 alpha) was administered to monkeys to determine if this altered the amount of scleral matrix metalloproteinases (MMPs). Experiments also were performed to determine whether the prostaglandin F (FP) receptor and gene transcripts are expressed in normal human sclera. Permeability of organ-cultured human sclera following prostaglandin exposure then was studied and the amount of MMP released into the medium measured. Finally, the permeability of human sclera to basic fibroblast growth factor (FGF-2) was determined following prostaglandin exposure. RESULTS: Topical prostaglandin administration that reduced scleral collagen also increased scleral MMP-1, MMP-2, and MMP-3 by 63 +/- 35%, 267 +/- 210%, and 729 +/- 500%, respectively. FP receptor protein was localized in scleral fibroblasts, and FP receptor gene transcript was identified in sclera. Exposure to prostaglandin F2 alpha, 17-phenyltrinor, PGF2 alpha, or latanoprost acid increased scleral permeability by up to 124%, 183%, or 213%, respectively. In these cultures, MMP-1, MMP-2, and MMP-3 were increased by up to 37%, 267%, and 96%, respectively. Finally, transscleral absorption of FGF-2 was increased by up to 126% with scleral exposure to latanoprost. CONCLUSIONS: These studies demonstrate that the sclera is metabolically active and pharmacologically responsive to prostaglandins. Further, they demonstrate the feasibility of cotreatment with prostaglandin to enhance transscleral delivery of peptides, such as growth factors and high-molecular-weight substances, to the posterior segment of the eye.

Full Text

The Full Text of this article is available as a PDF (675.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abramovitz M., Boie Y., Nguyen T., Rushmore T. H., Bayne M. A., Metters K. M., Slipetz D. M., Grygorczyk R. Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem. 1994 Jan 28;269(4):2632–2636. [PubMed] [Google Scholar]
  2. Ahmed I., Gokhale R. D., Shah M. V., Patton T. F. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J Pharm Sci. 1987 Aug;76(8):583–586. doi: 10.1002/jps.2600760802. [DOI] [PubMed] [Google Scholar]
  3. Ahmed I., Patton T. F. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci. 1985 Apr;26(4):584–587. [PubMed] [Google Scholar]
  4. Alexander R. A., Hiscott P. S., Hart R. L., Grierson I. Effect of melanin bleaching on immunoperoxidase, with reference to ocular tissues and lesions. Med Lab Sci. 1986 Apr;43(2):121–127. [PubMed] [Google Scholar]
  5. Ambati J., Canakis C. S., Miller J. W., Gragoudas E. S., Edwards A., Weissgold D. J., Kim I., Delori F. C., Adamis A. P. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1181–1185. [PubMed] [Google Scholar]
  6. Anand R., Nightingale S. D., Fish R. H., Smith T. J., Ashton P. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol. 1993 Feb;111(2):223–227. doi: 10.1001/archopht.1993.01090020077027. [DOI] [PubMed] [Google Scholar]
  7. Anthony T. L., Pierce K. L., Stamer W. D., Regan J. W. Prostaglandin F2 alpha receptors in the human trabecular meshwork. Invest Ophthalmol Vis Sci. 1998 Feb;39(2):315–321. [PubMed] [Google Scholar]
  8. Assil K. K., Frucht-Perry J., Ziegler E., Schanzlin D. J., Schneiderman T., Weinreb R. N. Tobramycin liposomes. Single subconjunctival therapy of pseudomonal keratitis. Invest Ophthalmol Vis Sci. 1991 Dec;32(13):3216–3220. [PubMed] [Google Scholar]
  9. Assil K. K., Hartzer M., Weinreb R. N., Nehorayan M., Ward T., Blumenkranz M. Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes. Invest Ophthalmol Vis Sci. 1991 Oct;32(11):2891–2897. [PubMed] [Google Scholar]
  10. Assil K. K., Lane J., Weinreb R. N. Sustained release of the antimetabolite 5-fluorouridine-5'-monophosphate by multivesicular liposomes. Ophthalmic Surg. 1988 Jun;19(6):408–413. [PubMed] [Google Scholar]
  11. Assil K. K., Weinreb R. N. Multivesicular liposomes. Sustained release of the antimetabolite cytarabine in the eye. Arch Ophthalmol. 1987 Mar;105(3):400–403. doi: 10.1001/archopht.1987.01060030120040. [DOI] [PubMed] [Google Scholar]
  12. Astin M. Effects of prostaglandin E2, F2alpha, and latanoprost acid on isolated ocular blood vessels in vitro. J Ocul Pharmacol Ther. 1998 Apr;14(2):119–128. doi: 10.1089/jop.1998.14.119. [DOI] [PubMed] [Google Scholar]
  13. BILL A. MOVEMENT OF ALBUMIN AND DEXTRAN THROUGH THE SCLERA. Arch Ophthalmol. 1965 Aug;74:248–252. doi: 10.1001/archopht.1965.00970040250024. [DOI] [PubMed] [Google Scholar]
  14. Barza M., Kane A., Baum J. L. Regional differences in ocular concentration of gentamicin after subconjunctival and retrobulbar injection in the rabbit. Am J Ophthalmol. 1977 Mar;83(3):407–413. doi: 10.1016/0002-9394(77)90741-3. [DOI] [PubMed] [Google Scholar]
  15. Barza M., Kane A., Baum J. Intraocular penetration of gentamicin after subconjunctibal and retrobulbar injection . Am J Ophthalmol. 1978 Apr;85(4):541–547. doi: 10.1016/s0002-9394(14)75252-3. [DOI] [PubMed] [Google Scholar]
  16. Bell C. L., Peppas N. A. Water, solute and protein diffusion in physiologically responsive hydrogels of poly (methacrylic acid-g-ethylene glycol). Biomaterials. 1996 Jun;17(12):1203–1218. doi: 10.1016/0142-9612(96)84941-6. [DOI] [PubMed] [Google Scholar]
  17. Berger A. S., Cheng C. K., Pearson P. A., Ashton P., Crooks P. A., Cynkowski T., Cynkowska G., Jaffe G. J. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1996 Oct;37(11):2318–2325. [PubMed] [Google Scholar]
  18. Berman M. B. Regulation of corneal fibroblast MMP-1 collagenase secretion by plasmin. Cornea. 1993 Sep;12(5):420–432. doi: 10.1097/00003226-199309000-00009. [DOI] [PubMed] [Google Scholar]
  19. Bikfalvi A., Klein S., Pintucci G., Rifkin D. B. Biological roles of fibroblast growth factor-2. Endocr Rev. 1997 Feb;18(1):26–45. doi: 10.1210/edrv.18.1.0292. [DOI] [PubMed] [Google Scholar]
  20. Bode W., Fernandez-Catalan C., Grams F., Gomis-Rüth F. X., Nagase H., Tschesche H., Maskos K. Insights into MMP-TIMP interactions. Ann N Y Acad Sci. 1999 Jun 30;878:73–91. doi: 10.1111/j.1749-6632.1999.tb07675.x. [DOI] [PubMed] [Google Scholar]
  21. Brannon-Peppas L., Peppas N. A. Dynamic and equilibrium swelling behaviour of pH-sensitive hydrogels containing 2-hydroxyethyl methacrylate. Biomaterials. 1990 Nov;11(9):635–644. doi: 10.1016/0142-9612(90)90021-h. [DOI] [PubMed] [Google Scholar]
  22. Brockhurst R. J. Vortex vein decompression for nanophthalmic uveal effusion. Arch Ophthalmol. 1980 Nov;98(11):1987–1990. doi: 10.1001/archopht.1980.01020040839008. [DOI] [PubMed] [Google Scholar]
  23. Caffé A. R., Söderpalm A. K., Holmqvist I., van Veen T. A combination of CNTF and BDNF rescues rd photoreceptors but changes rod differentiation in the presence of RPE in retinal explants. Invest Ophthalmol Vis Sci. 2001 Jan;42(1):275–282. [PubMed] [Google Scholar]
  24. Chapman S. A., Ayad S., O'Donoghue E., Bonshek R. E. Glycoproteins of trabecular meshwork, cornea and sclera. Eye (Lond) 1998;12(Pt 3A):440–448. doi: 10.1038/eye.1998.102. [DOI] [PubMed] [Google Scholar]
  25. Cheng C. K., Berger A. S., Pearson P. A., Ashton P., Jaffe G. J. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci. 1995 Feb;36(2):442–453. [PubMed] [Google Scholar]
  26. Chong N. H., Alexander R. A., Waters L., Barnett K. C., Bird A. C., Luthert P. J. Repeated injections of a ciliary neurotrophic factor analogue leading to long-term photoreceptor survival in hereditary retinal degeneration. Invest Ophthalmol Vis Sci. 1999 May;40(6):1298–1305. [PubMed] [Google Scholar]
  27. Connor B., Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Brain Res Rev. 1998 Jun;27(1):1–39. doi: 10.1016/s0165-0173(98)00004-6. [DOI] [PubMed] [Google Scholar]
  28. Cook H., Davies K. J., Harding K. G., Thomas D. W. Defective extracellular matrix reorganization by chronic wound fibroblasts is associated with alterations in TIMP-1, TIMP-2, and MMP-2 activity. J Invest Dermatol. 2000 Aug;115(2):225–233. doi: 10.1046/j.1523-1747.2000.00044.x. [DOI] [PubMed] [Google Scholar]
  29. Cummings B. J., Yee G. J., Cotman C. W. bFGF promotes the survival of entorhinal layer II neurons after perforant path axotomy. Brain Res. 1992 Sep 25;591(2):271–276. doi: 10.1016/0006-8993(92)91707-l. [DOI] [PubMed] [Google Scholar]
  30. Cunha-Vaz J. G., Shakib M., Ashton N. Studies on the permeability of the blood-retinal barrier. I. On the existence, development, and site of a blood-retinal barrier. Br J Ophthalmol. 1966 Aug;50(8):441–453. doi: 10.1136/bjo.50.8.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Dan J. A., Yaron A. Focal scleral permeability enhanced by collagenase digestion. Experimental model of enzymatic sclerostomy. Ophthalmology. 1994 Mar;101(3):461–472. doi: 10.1016/s0161-6420(94)31311-x. [DOI] [PubMed] [Google Scholar]
  32. Denhardt D. T., Feng B., Edwards D. R., Cocuzzi E. T., Malyankar U. M. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther. 1993 Sep;59(3):329–341. doi: 10.1016/0163-7258(93)90074-n. [DOI] [PubMed] [Google Scholar]
  33. Dreyfus H., Sahel J., Heidinger V., Mohand-Said S., Guérold B., Meuillet E., Fontaine V., Hicks D. Gangliosides and neurotrophic growth factors in the retina. Molecular interactions and applications as neuroprotective agents. Ann N Y Acad Sci. 1998 Jun 19;845:240–252. doi: 10.1111/j.1749-6632.1998.tb09677.x. [DOI] [PubMed] [Google Scholar]
  34. Edelhauser H. F., Maren T. H. Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors. Arch Ophthalmol. 1988 Aug;106(8):1110–1115. doi: 10.1001/archopht.1988.01060140266039. [DOI] [PubMed] [Google Scholar]
  35. Fontaine V., Kinkl N., Sahel J., Dreyfus H., Hicks D. Survival of purified rat photoreceptors in vitro is stimulated directly by fibroblast growth factor-2. J Neurosci. 1998 Dec 1;18(23):9662–9672. doi: 10.1523/JNEUROSCI.18-23-09662.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Foss A. J., Alexander R. A., Jefferies L. W., Lightman S. Immunohistochemical techniques: the effect of melanin bleaching. Br J Biomed Sci. 1995 Mar;52(1):22–25. [PubMed] [Google Scholar]
  37. Foulds W. S. Doyne Memorial Lecture, 1976. Clinical significance of trans-scleral fluid transfer. Trans Ophthalmol Soc U K. 1976 Jul;96(2):290–308. [PubMed] [Google Scholar]
  38. Gass J. D. Uveal effusion syndrome. A new hypothesis concerning pathogenesis and technique of surgical treatment. Retina. 1983;3(3):159–163. [PubMed] [Google Scholar]
  39. Gaton D. D., Sagara T., Lindsey J. D., Weinreb R. N. Matrix metalloproteinase-1 localization in the normal human uveoscleral outflow pathway. Invest Ophthalmol Vis Sci. 1999 Feb;40(2):363–369. [PubMed] [Google Scholar]
  40. Goldberg G. I., Strongin A., Collier I. E., Genrich L. T., Marmer B. L. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem. 1992 Mar 5;267(7):4583–4591. [PubMed] [Google Scholar]
  41. Grayson M. C., Laties A. M. Ocular localization of sodium fluorescein. Effects of administration in rabbit and monkey. Arch Ophthalmol. 1971 May;85(5):600–passim. doi: 10.1001/archopht.1971.00990050602014. [DOI] [PubMed] [Google Scholar]
  42. Gross D. S., Rothfeld J. M. Quantitative immunocytochemistry of hypothalamic and pituitary hormones: validation of an automated, computerized image analysis system. J Histochem Cytochem. 1985 Jan;33(1):11–20. doi: 10.1177/33.1.2578140. [DOI] [PubMed] [Google Scholar]
  43. Hackett S. F., Schoenfeld C. L., Freund J., Gottsch J. D., Bhargave S., Campochiaro P. A. Neurotrophic factors, cytokines and stress increase expression of basic fibroblast growth factor in retinal pigmented epithelial cells. Exp Eye Res. 1997 Jun;64(6):865–873. doi: 10.1006/exer.1996.0256. [DOI] [PubMed] [Google Scholar]
  44. Hicks D., Courtois Y. Fibroblast growth factor stimulates photoreceptor differentiation in vitro. J Neurosci. 1992 Jun;12(6):2022–2033. doi: 10.1523/JNEUROSCI.12-06-02022.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Horner P. J., Gage F. H. Regenerating the damaged central nervous system. Nature. 2000 Oct 26;407(6807):963–970. doi: 10.1038/35039559. [DOI] [PubMed] [Google Scholar]
  46. Huang Y., Gil D. W., Vanscheeuwijck P., Stamer W. D., Regan J. W. Localization of alpha 2-adrenergic receptor subtypes in the anterior segment of the human eye with selective antibodies. Invest Ophthalmol Vis Sci. 1995 Dec;36(13):2729–2739. [PubMed] [Google Scholar]
  47. Inomata H., Bill A. Exit sites of uveoscleral flow of aqueous humor in cynomolgus monkey eyes. Exp Eye Res. 1977 Aug;25(2):113–118. doi: 10.1016/0014-4835(77)90123-3. [DOI] [PubMed] [Google Scholar]
  48. Ip N. Y. The neurotrophins and neuropoietic cytokines: two families of growth factors acting on neural and hematopoietic cells. Ann N Y Acad Sci. 1998 May 1;840:97–106. doi: 10.1111/j.1749-6632.1998.tb09553.x. [DOI] [PubMed] [Google Scholar]
  49. Jaffe G. J., Yang C. H., Guo H., Denny J. P., Lima C., Ashton P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3569–3575. [PubMed] [Google Scholar]
  50. Jaffe G. J., Yang C. S., Wang X. C., Cousins S. W., Gallemore R. P., Ashton P. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. 1998 Jan;105(1):46–56. doi: 10.1016/s0161-6420(98)91176-9. [DOI] [PubMed] [Google Scholar]
  51. Johnston M. C., Noden D. M., Hazelton R. D., Coulombre J. L., Coulombre A. J. Origins of avian ocular and periocular tissues. Exp Eye Res. 1979 Jul;29(1):27–43. doi: 10.1016/0014-4835(79)90164-7. [DOI] [PubMed] [Google Scholar]
  52. Kamei M., Misono K., Lewis H. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. Am J Ophthalmol. 1999 Dec;128(6):739–746. doi: 10.1016/s0002-9394(99)00239-1. [DOI] [PubMed] [Google Scholar]
  53. Keeley F. W., Morin J. D., Vesely S. Characterization of collagen from normal human sclera. Exp Eye Res. 1984 Nov;39(5):533–542. doi: 10.1016/0014-4835(84)90053-8. [DOI] [PubMed] [Google Scholar]
  54. Kimura S., Kobayashi M., Nakamura M., Hirano K., Awaya S., Hoshino T. Immunoelectron microscopic localization of decorin in aged human corneal and scleral stroma. J Electron Microsc (Tokyo) 1995 Dec;44(6):445–449. [PubMed] [Google Scholar]
  55. Komai Y., Ushiki T. The three-dimensional organization of collagen fibrils in the human cornea and sclera. Invest Ophthalmol Vis Sci. 1991 Jul;32(8):2244–2258. [PubMed] [Google Scholar]
  56. Kumar S., Haglund B. O., Himmelstein K. J. In situ-forming gels for ophthalmic drug delivery. J Ocul Pharmacol. 1994 Spring;10(1):47–56. doi: 10.1089/jop.1994.10.47. [DOI] [PubMed] [Google Scholar]
  57. LaVail M. M., Yasumura D., Matthes M. T., Lau-Villacorta C., Unoki K., Sung C. H., Steinberg R. H. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci. 1998 Mar;39(3):592–602. [PubMed] [Google Scholar]
  58. Lalani E. N., Golding M., Hudson M., Chieffi G., Stamp G., Anilkumar T. V., Sarraf C., Alison M. R. Protein extraction and western blotting from methacarn-fixed tissue. J Pathol. 1995 Nov;177(3):323–328. doi: 10.1002/path.1711770316. [DOI] [PubMed] [Google Scholar]
  59. Lam T. T., Fu J., Tso M. O. A histopathologic study of retinal lesions inflicted by transscleral iontophoresis. Graefes Arch Clin Exp Ophthalmol. 1991;229(4):389–394. doi: 10.1007/BF00170699. [DOI] [PubMed] [Google Scholar]
  60. Laties A. M., Rapoport S. The blood-ocular barriers under osmotic stress. Studies on the freeze-dried eye. Arch Ophthalmol. 1976 Jul;94(7):1086–1091. doi: 10.1001/archopht.1976.03910040006002. [DOI] [PubMed] [Google Scholar]
  61. Lee V. H., Carson L. W., Kashi S. D., Stratford R. E., Jr Metabolic and permeation barriers to the ocular absorption of topically applied enkephalins in albino rabbits. J Ocul Pharmacol. 1986 Fall;2(4):345–352. doi: 10.1089/jop.1986.2.345. [DOI] [PubMed] [Google Scholar]
  62. Lee V. H., Robinson J. R. Topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol. 1986 Winter;2(1):67–108. doi: 10.1089/jop.1986.2.67. [DOI] [PubMed] [Google Scholar]
  63. Lim J. I., Maguire A. M., John G., Mohler M. A., Fiscella R. G. Intraocular tissue plasminogen activator concentrations after subconjunctival delivery. Ophthalmology. 1993 Mar;100(3):373–376. doi: 10.1016/s0161-6420(93)31639-8. [DOI] [PubMed] [Google Scholar]
  64. Lincoff H., Stanga P., Movshovich A., Palleroni A., Madjarov B., Rivera R., Silverman R. Choroidal concentration of interferon after retrobulbar injection. Invest Ophthalmol Vis Sci. 1996 Dec;37(13):2768–2771. [PubMed] [Google Scholar]
  65. Lindsay R. M. Therapeutic potential of the neurotrophins and neurotrophin-CNTF combinations in peripheral neuropathies and motor neuron diseases. Ciba Found Symp. 1996;196:39–53. [PubMed] [Google Scholar]
  66. Lindsey J. D., Kashiwagi K., Boyle D., Kashiwagi F., Firestein G. S., Weinreb R. N. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996 Aug;15(8):869–875. doi: 10.3109/02713689609017628. [DOI] [PubMed] [Google Scholar]
  67. Lindsey J. D., Kashiwagi K., Kashiwagi F., Weinreb R. N. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci. 1997 Oct;38(11):2214–2223. [PubMed] [Google Scholar]
  68. Lindsey J. D., To H. D., Weinreb R. N. Induction of c-fos by prostaglandin F2 alpha in human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1994 Jan;35(1):242–250. [PubMed] [Google Scholar]
  69. Lindsey J. D., Weinreb R. N. Survival and differentiation of purified retinal ganglion cells in a chemically defined microenvironment. Invest Ophthalmol Vis Sci. 1994 Sep;35(10):3640–3648. [PubMed] [Google Scholar]
  70. Lipton S. A., Wagner J. A., Madison R. D., D'Amore P. A. Acidic fibroblast growth factor enhances regeneration of processes by postnatal mammalian retinal ganglion cells in culture. Proc Natl Acad Sci U S A. 1988 Apr;85(7):2388–2392. doi: 10.1073/pnas.85.7.2388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. MCCARTNEY H. J., DRYSDALE I. O., GORNALL A. G., BASU P. K. AN AUTORADIOGRAPHIC STUDY OF THE PENETRATION OF SUBCONJUNCTIVALLY INJECTED HYDROCORTISONE INTO THE NORMAL AND INFLAMED RABBIT EYE. Invest Ophthalmol. 1965 Jun;4:297–302. [PubMed] [Google Scholar]
  72. Martin D. F., Parks D. J., Mellow S. D., Ferris F. L., Walton R. C., Remaley N. A., Chew E. Y., Ashton P., Davis M. D., Nussenblatt R. B. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol. 1994 Dec;112(12):1531–1539. doi: 10.1001/archopht.1994.01090240037023. [DOI] [PubMed] [Google Scholar]
  73. Matrisian L. M. The matrix-degrading metalloproteinases. Bioessays. 1992 Jul;14(7):455–463. doi: 10.1002/bies.950140705. [DOI] [PubMed] [Google Scholar]
  74. Maurice D. M., Polgar J. Diffusion across the sclera. Exp Eye Res. 1977 Dec;25(6):577–582. doi: 10.1016/0014-4835(77)90136-1. [DOI] [PubMed] [Google Scholar]
  75. Nagase H., Fields G. B. Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Biopolymers. 1996;40(4):399–416. doi: 10.1002/(SICI)1097-0282(1996)40:4%3C399::AID-BIP5%3E3.0.CO;2-R. [DOI] [PubMed] [Google Scholar]
  76. Nagase H., Suzuki K., Enghild J. J., Salvesen G. Stepwise activation mechanisms of the precursors of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin). Biomed Biochim Acta. 1991;50(4-6):749–754. [PubMed] [Google Scholar]
  77. Nagase H., Woessner J. F., Jr Matrix metalloproteinases. J Biol Chem. 1999 Jul 30;274(31):21491–21494. doi: 10.1074/jbc.274.31.21491. [DOI] [PubMed] [Google Scholar]
  78. Nakata N., Kato H., Kogure K. Protective effects of basic fibroblast growth factor against hippocampal neuronal damage following cerebral ischemia in the gerbil. Brain Res. 1993 Mar 12;605(2):354–356. doi: 10.1016/0006-8993(93)91766-l. [DOI] [PubMed] [Google Scholar]
  79. Ocklind A., Lake S., Wentzel P., Nistér M., Stjernschantz J. Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomolgus monkey eye. Invest Ophthalmol Vis Sci. 1996 Apr;37(5):716–726. [PubMed] [Google Scholar]
  80. Olsen T. W., Aaberg S. Y., Geroski D. H., Edelhauser H. F. Human sclera: thickness and surface area. Am J Ophthalmol. 1998 Feb;125(2):237–241. doi: 10.1016/s0002-9394(99)80096-8. [DOI] [PubMed] [Google Scholar]
  81. Olsen T. W., Edelhauser H. F., Lim J. I., Geroski D. H. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995 Aug;36(9):1893–1903. [PubMed] [Google Scholar]
  82. Parsons S. L., Watson S. A., Brown P. D., Collins H. M., Steele R. J. Matrix metalloproteinases. Br J Surg. 1997 Feb;84(2):160–166. [PubMed] [Google Scholar]
  83. Pearce R. K., Collins P., Jenner P., Emmett C., Marsden C. D. Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP-treated common marmoset. Synapse. 1996 Jul;23(3):192–200. doi: 10.1002/(SICI)1098-2396(199607)23:3<192::AID-SYN8>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  84. Pearson P. A., Jaffe G. J., Martin D. F., Cordahi G. J., Grossniklaus H., Schmeisser E. T., Ashton P. Evaluation of a delivery system providing long-term release of cyclosporine. Arch Ophthalmol. 1996 Mar;114(3):311–317. doi: 10.1001/archopht.1996.01100130307014. [DOI] [PubMed] [Google Scholar]
  85. Pease M. E., McKinnon S. J., Quigley H. A., Kerrigan-Baumrind L. A., Zack D. J. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000 Mar;41(3):764–774. [PubMed] [Google Scholar]
  86. Penc S. F., Pomahac B., Winkler T., Dorschner R. A., Eriksson E., Herndon M., Gallo R. L. Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function. J Biol Chem. 1998 Oct 23;273(43):28116–28121. doi: 10.1074/jbc.273.43.28116. [DOI] [PubMed] [Google Scholar]
  87. Peyman G. A., Bok D. Peroxidase diffusion in the normal and laser-coagulated primate retina. Invest Ophthalmol. 1972 Jan;11(1):35–45. [PubMed] [Google Scholar]
  88. Pierce K. L., Fujino H., Srinivasan D., Regan J. W. Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton. J Biol Chem. 1999 Dec 10;274(50):35944–35949. doi: 10.1074/jbc.274.50.35944. [DOI] [PubMed] [Google Scholar]
  89. Pino R. M. Restriction to endogenous plasma proteins by a fenestrated capillary endothelium: an ultrastructural immunocytochemical study of the choriocapillary endothelium. Am J Anat. 1985 Apr;172(4):279–289. doi: 10.1002/aja.1001720403. [DOI] [PubMed] [Google Scholar]
  90. Rabchevsky A. G., Fugaccia I., Fletcher-Turner A., Blades D. A., Mattson M. P., Scheff S. W. Basic fibroblast growth factor (bFGF) enhances tissue sparing and functional recovery following moderate spinal cord injury. J Neurotrauma. 1999 Sep;16(9):817–830. doi: 10.1089/neu.1999.16.817. [DOI] [PubMed] [Google Scholar]
  91. Rada J. A., Achen V. R., Perry C. A., Fox P. W. Proteoglycans in the human sclera. Evidence for the presence of aggrecan. Invest Ophthalmol Vis Sci. 1997 Aug;38(9):1740–1751. [PubMed] [Google Scholar]
  92. Raviola G., Freddo T. F. A simple staining method for blood vessels in flat preparations of ocular tissues. Invest Ophthalmol Vis Sci. 1980 Dec;19(12):1518–1521. [PubMed] [Google Scholar]
  93. Rudnick D. E., Noonan J. S., Geroski D. H., Prausnitz M. R., Edelhauser H. F. The effect of intraocular pressure on human and rabbit scleral permeability. Invest Ophthalmol Vis Sci. 1999 Nov;40(12):3054–3058. [PubMed] [Google Scholar]
  94. Sagara T., Gaton D. D., Lindsey J. D., Gabelt B. T., Kaufman P. L., Weinreb R. N. Reduction of collagen type I in the ciliary muscle of inflamed monkey eyes. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2568–2576. [PubMed] [Google Scholar]
  95. Sagara T., Gaton D. D., Lindsey J. D., Gabelt B. T., Kaufman P. L., Weinreb R. N. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999 Jun;117(6):794–801. doi: 10.1001/archopht.117.6.794. [DOI] [PubMed] [Google Scholar]
  96. Sanborn G. E., Anand R., Torti R. E., Nightingale S. D., Cal S. X., Yates B., Ashton P., Smith T. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol. 1992 Feb;110(2):188–195. doi: 10.1001/archopht.1992.01080140044023. [DOI] [PubMed] [Google Scholar]
  97. Sarraf D., Lee D. A. The role of iontophoresis in ocular drug delivery. J Ocul Pharmacol. 1994 Spring;10(1):69–81. doi: 10.1089/jop.1994.10.69. [DOI] [PubMed] [Google Scholar]
  98. Schoenwald R. D. Ocular drug delivery. Pharmacokinetic considerations. Clin Pharmacokinet. 1990 Apr;18(4):255–269. doi: 10.2165/00003088-199018040-00001. [DOI] [PubMed] [Google Scholar]
  99. Shetye J. D., Scheynius A., Mellstedt H. T., Biberfeld P. Retrieval of leukocyte antigens in paraffin-embedded rat tissues. J Histochem Cytochem. 1996 Jul;44(7):767–776. doi: 10.1177/44.7.8675998. [DOI] [PubMed] [Google Scholar]
  100. Shields M. B., Bradbury M. J., Shelburne J. D., Bell S. W. The permeability of the outer layers of limbus and anterior sclera. Invest Ophthalmol Vis Sci. 1977 Sep;16(9):866–869. [PubMed] [Google Scholar]
  101. Shields M. B., Shelburne J. D., Bell S. W. The ultrastructure of human limbal collagen. Invest Ophthalmol Vis Sci. 1977 Sep;16(9):864–866. [PubMed] [Google Scholar]
  102. Shuttleworth C. A. Type VIII collagen. Int J Biochem Cell Biol. 1997 Oct;29(10):1145–1148. doi: 10.1016/s1357-2725(97)00033-2. [DOI] [PubMed] [Google Scholar]
  103. Skuta G. L., Assil K., Parrish R. K., 2nd, Folberg R., Weinreb R. N. Filtering surgery in owl monkeys treated with the antimetabolite 5-fluorouridine 5'-monophosphate entrapped in multivesicular liposomes. Am J Ophthalmol. 1987 May 15;103(5):714–716. doi: 10.1016/s0002-9394(14)74340-5. [DOI] [PubMed] [Google Scholar]
  104. Smith R. S., Rudt L. A. Ocular vascular and epithelial barriers to microperoxidase. Invest Ophthalmol. 1975 Jul;14(7):556–560. [PubMed] [Google Scholar]
  105. Smith T. J., Pearson P. A., Blandford D. L., Brown J. D., Goins K. A., Hollins J. L., Schmeisser E. T., Glavinos P., Baldwin L. B., Ashton P. Intravitreal sustained-release ganciclovir. Arch Ophthalmol. 1992 Feb;110(2):255–258. doi: 10.1001/archopht.1992.01080140111037. [DOI] [PubMed] [Google Scholar]
  106. Spitznas M. The fine structure of human scleral collagen. Am J Ophthalmol. 1971 Jan;71(1 Pt 1):68–68. doi: 10.1016/0002-9394(71)91095-6. [DOI] [PubMed] [Google Scholar]
  107. Stamer W. D., Seftor R. E., Snyder R. W., Regan J. W. Cultured human trabecular meshwork cells express aquaporin-1 water channels. Curr Eye Res. 1995 Dec;14(12):1095–1100. doi: 10.3109/02713689508995815. [DOI] [PubMed] [Google Scholar]
  108. Stjernschantz J., Selén G., Astin M., Resul B. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment. Prog Retin Eye Res. 2000 Jul;19(4):459–496. doi: 10.1016/s1350-9462(00)00003-3. [DOI] [PubMed] [Google Scholar]
  109. Stjernschantz J., Selén G., Sjöquist B., Resul B. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:513–518. [PubMed] [Google Scholar]
  110. Takeuchi A., Kricorian G., Yao X. Y., Kenny J. W., Marmor M. F. The rate and source of albumin entry into saline-filled experimental retinal detachments. Invest Ophthalmol Vis Sci. 1994 Oct;35(11):3792–3798. [PubMed] [Google Scholar]
  111. Thale A., Tillmann B., Rochels R. Scanning electron-microscopic studies of the collagen architecture of the human sclera--normal and pathological findings. Ophthalmologica. 1996;210(3):137–141. doi: 10.1159/000310693. [DOI] [PubMed] [Google Scholar]
  112. Thale A., Tillmann B. The collagen architecture of the sclera--SEM and immunohistochemical studies. Ann Anat. 1993 Jun;175(3):215–220. doi: 10.1016/s0940-9602(11)80004-x. [DOI] [PubMed] [Google Scholar]
  113. Toris C. B., Pederson J. E. Experimental retinal detachment. VII. Intravenous horseradish peroxidase diffusion across the blood-retinal barrier. Arch Ophthalmol. 1984 May;102(5):752–756. doi: 10.1001/archopht.1984.01040030600030. [DOI] [PubMed] [Google Scholar]
  114. Trelstad R. L., Silbermann N. N., Brockhurst R. J. Nanophthalmic sclera. Ultrastructural, histochemical, and biochemical observations. Arch Ophthalmol. 1982 Dec;100(12):1935–1938. doi: 10.1001/archopht.1982.01030040915009. [DOI] [PubMed] [Google Scholar]
  115. Trier K., Olsen E. B., Ammitzbøll T. Regional glycosaminoglycans composition of the human sclera. Acta Ophthalmol (Copenh) 1990 Jun;68(3):304–306. doi: 10.1111/j.1755-3768.1990.tb01926.x. [DOI] [PubMed] [Google Scholar]
  116. Tso M. O., Shih C. Y., McLean I. W. Is there a blood-brain barrier at the optic nerve head? Arch Ophthalmol. 1975 Sep;93(9):815–825. doi: 10.1001/archopht.1975.01010020703008. [DOI] [PubMed] [Google Scholar]
  117. Unlu N., Robinson J. R. Scleral permeability to hydrocortisone and mannitol in the albino rabbit eye. J Ocul Pharmacol Ther. 1998 Jun;14(3):273–281. doi: 10.1089/jop.1998.14.273. [DOI] [PubMed] [Google Scholar]
  118. Velez G., Whitcup S. M. New developments in sustained release drug delivery for the treatment of intraocular disease. Br J Ophthalmol. 1999 Nov;83(11):1225–1229. doi: 10.1136/bjo.83.11.1225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Vincenti M. P., White L. A., Schroen D. J., Benbow U., Brinckerhoff C. E. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr. 1996;6(4):391–411. doi: 10.1615/critreveukargeneexpr.v6.i4.40. [DOI] [PubMed] [Google Scholar]
  120. Virgilio L. A., Williams R. J., Klintworth G. K. An unusually large human eye with abnormal scleral collagen. Arch Ophthalmol. 1976 Jan;94(1):101–105. doi: 10.1001/archopht.1976.03910030047012. [DOI] [PubMed] [Google Scholar]
  121. Walicke P., Cowan W. M., Ueno N., Baird A., Guillemin R. Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension. Proc Natl Acad Sci U S A. 1986 May;83(9):3012–3016. doi: 10.1073/pnas.83.9.3012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Weijtens O., Schoemaker R. C., Lentjes E. G., Romijn F. P., Cohen A. F., van Meurs J. C. Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. Ophthalmology. 2000 Oct;107(10):1932–1938. doi: 10.1016/s0161-6420(00)00344-4. [DOI] [PubMed] [Google Scholar]
  123. Weijtens O., van der Sluijs F. A., Schoemaker R. C., Lentjes E. G., Cohen A. F., Romijn F. P., van Meurs J. C. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am J Ophthalmol. 1997 Mar;123(3):358–363. doi: 10.1016/s0002-9394(14)70131-x. [DOI] [PubMed] [Google Scholar]
  124. Weinreb R. N., Kashiwagi K., Kashiwagi F., Tsukahara S., Lindsey J. D. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997 Dec;38(13):2772–2780. [PubMed] [Google Scholar]
  125. Weinreb R. N., Levin L. A. Is neuroprotection a viable therapy for glaucoma? Arch Ophthalmol. 1999 Nov;117(11):1540–1544. doi: 10.1001/archopht.117.11.1540. [DOI] [PubMed] [Google Scholar]
  126. Wessel H., Anderson S., Fite D., Halvas E., Hempel J., SundarRaj N. Type XII collagen contributes to diversities in human corneal and limbal extracellular matrices. Invest Ophthalmol Vis Sci. 1997 Oct;38(11):2408–2422. [PubMed] [Google Scholar]
  127. Westermarck J., Holmström T., Ahonen M., Eriksson J. E., Kähäri V. M. Enhancement of fibroblast collagenase-1 (MMP-1) gene expression by tumor promoter okadaic acid is mediated by stress-activated protein kinases Jun N-terminal kinase and p38. Matrix Biol. 1998 Dec;17(8-9):547–557. doi: 10.1016/s0945-053x(98)90107-x. [DOI] [PubMed] [Google Scholar]
  128. White J., Werkmeister J. A., Ramshaw J. A., Birk D. E. Organization of fibrillar collagen in the human and bovine cornea: collagen types V and III. Connect Tissue Res. 1997;36(3):165–174. doi: 10.3109/03008209709160218. [DOI] [PubMed] [Google Scholar]
  129. Woessner J. F., Jr The family of matrix metalloproteinases. Ann N Y Acad Sci. 1994 Sep 6;732:11–21. doi: 10.1111/j.1749-6632.1994.tb24720.x. [DOI] [PubMed] [Google Scholar]
  130. Wood R. L., Koseki T., Kelly D. E. Uveoscleral permeability to intracamerally infused ferritin in eyes of rabbits and monkeys. Cell Tissue Res. 1992 Dec;270(3):559–567. doi: 10.1007/BF00645059. [DOI] [PubMed] [Google Scholar]
  131. Yamabayashi S., Ohno S., Aguilar R. N., Furuya T., Hosoda M., Tsukahara S. Ultrastructural studies of collagen fibers of the cornea and sclera by a quick-freezing and deep-etching method. Ophthalmic Res. 1991;23(6):320–329. doi: 10.1159/000267129. [DOI] [PubMed] [Google Scholar]
  132. Yang C. S., Khawly J. A., Hainsworth D. P., Chen S. N., Ashton P., Guo H., Jaffe G. J. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol. 1998 Jan;116(1):69–77. doi: 10.1001/archopht.116.1.69. [DOI] [PubMed] [Google Scholar]
  133. Yue B. Y., Duvall J., Goldberg M. F., Puck A., Tso M. O., Sugar J. Nanophthalmic sclera. Morphologic and tissue culture studies. Ophthalmology. 1986 Apr;93(4):534–541. doi: 10.1016/s0161-6420(86)33704-7. [DOI] [PubMed] [Google Scholar]
  134. Zhou T., Lewis H., Foster R. E., Schwendeman S. P. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J Control Release. 1998 Nov 13;55(2-3):281–295. doi: 10.1016/s0168-3659(98)00061-3. [DOI] [PubMed] [Google Scholar]
  135. van der Loos C. M., Marijianowski M. M., Becker A. E. Quantification in immunohistochemistry: the measurement of the ratios of collagen types I and II. Histochem J. 1994 Apr;26(4):347–354. doi: 10.1007/BF00157768. [DOI] [PubMed] [Google Scholar]

Articles from Transactions of the American Ophthalmological Society are provided here courtesy of American Ophthalmological Society

RESOURCES